JP2016507504A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016507504A5 JP2016507504A5 JP2015549830A JP2015549830A JP2016507504A5 JP 2016507504 A5 JP2016507504 A5 JP 2016507504A5 JP 2015549830 A JP2015549830 A JP 2015549830A JP 2015549830 A JP2015549830 A JP 2015549830A JP 2016507504 A5 JP2016507504 A5 JP 2016507504A5
- Authority
- JP
- Japan
- Prior art keywords
- following structure
- compound according
- represented
- group
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims 5
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000003832 immune regulation Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- 0 *C(*1C(*)=*C(*)=*1)C(*C1=C(*)*(c(cc2)ccc2I)N=P1)=O Chemical compound *C(*1C(*)=*C(*)=*1)C(*C1=C(*)*(c(cc2)ccc2I)N=P1)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745444P | 2012-12-21 | 2012-12-21 | |
| US61/745,444 | 2012-12-21 | ||
| PCT/US2013/077257 WO2014100735A2 (en) | 2012-12-21 | 2013-12-20 | Diazole amides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016507504A JP2016507504A (ja) | 2016-03-10 |
| JP2016507504A5 true JP2016507504A5 (enExample) | 2017-02-02 |
| JP6306607B2 JP6306607B2 (ja) | 2018-04-04 |
Family
ID=50975330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549830A Active JP6306607B2 (ja) | 2012-12-21 | 2013-12-20 | ジアゾールアミド |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9169248B2 (enExample) |
| EP (1) | EP2935227B1 (enExample) |
| JP (1) | JP6306607B2 (enExample) |
| CN (1) | CN104918921B (enExample) |
| AU (1) | AU2013364038B2 (enExample) |
| CA (1) | CA2894715C (enExample) |
| DK (1) | DK2935227T3 (enExample) |
| ES (1) | ES2648994T3 (enExample) |
| MX (1) | MX2015007853A (enExample) |
| PT (1) | PT2935227T (enExample) |
| WO (1) | WO2014100735A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014089495A1 (en) | 2012-12-07 | 2014-06-12 | Chemocentryx, Inc. | Diazole lactams |
| EP2935227B1 (en) | 2012-12-21 | 2017-09-13 | ChemoCentryx, Inc. | Diazole amides as ccr1 receptor antagonists |
| WO2016202759A1 (en) * | 2015-06-18 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Cytotoxic substituted 2-(1 h-pyrazol-1 -yl)-1,3-benzothiazole compounds for the treatment of cancer |
| WO2016202758A1 (en) | 2015-06-18 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds |
| PL3439653T3 (pl) | 2016-04-07 | 2021-07-05 | Chemocentryx, Inc. | Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1 |
| EP3818044A1 (en) * | 2018-07-03 | 2021-05-12 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CA3145303A1 (en) | 2019-07-10 | 2021-01-14 | Chemocentryx, Inc. | Indanes as pd-l1 inhibitors |
| EP4045037A4 (en) | 2019-10-16 | 2023-11-15 | ChemoCentryx, Inc. | HETEROARYL-BIPHENYL AMINE FOR THE TREATMENT OF PD-L1 DISEASE |
| EP4045036A4 (en) | 2019-10-16 | 2023-11-15 | ChemoCentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2012100A (en) * | 1931-12-17 | 1935-08-20 | Edwin Pierce Weber | Liquid fuel burner |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
| US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
| US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
| WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
| WO1991012779A1 (en) | 1990-02-28 | 1991-09-05 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
| US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
| US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
| US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
| JPH11513382A (ja) * | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 |
| DE19539091A1 (de) * | 1995-10-20 | 1997-04-24 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung |
| US5833651A (en) | 1996-11-08 | 1998-11-10 | Medtronic, Inc. | Therapeutic intraluminal stents |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6756385B2 (en) * | 2000-07-31 | 2004-06-29 | Pfizer Inc. | Imidazole derivatives |
| GT200100147A (es) * | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
| KR20030030029A (ko) * | 2000-09-22 | 2003-04-16 | 니혼노야쿠가부시키가이샤 | Ｎ-(4-피라졸릴)아미드 유도체 및 농원예용 약제 그리고그 사용방법 |
| US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
| BRPI0409949A (pt) | 2003-05-01 | 2006-04-25 | Bristol Myers Squibb Co | compostos de pirazol amida aril-substituìda úteis como inibidores de cinase |
| EP1883646A1 (en) | 2005-05-19 | 2008-02-06 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| CA2675511A1 (en) * | 2006-10-10 | 2008-04-17 | Amgen Inc. | N-aryl pyrazole compounds for use against diabetes |
| EP2170309B1 (en) * | 2007-06-22 | 2016-10-26 | Hydra Biosciences, Inc. | 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel |
| EP2297112B1 (en) * | 2008-05-06 | 2013-04-03 | Boehringer Ingelheim International GmbH | Pyrazole compounds as ccr1 antagonists |
| US20120108614A1 (en) * | 2008-05-14 | 2012-05-03 | Chong Jayhong A | Compounds and compositions for treating chemical warfare agent-induced injuries |
| WO2010053861A2 (en) * | 2008-11-07 | 2010-05-14 | H. Lundbeck A/S | Biologically active amides |
| GB0915892D0 (en) * | 2009-09-10 | 2009-10-14 | Smithkline Beecham Corp | Compounds |
| WO2014089495A1 (en) * | 2012-12-07 | 2014-06-12 | Chemocentryx, Inc. | Diazole lactams |
| EP2935227B1 (en) | 2012-12-21 | 2017-09-13 | ChemoCentryx, Inc. | Diazole amides as ccr1 receptor antagonists |
-
2013
- 2013-12-20 EP EP13866291.1A patent/EP2935227B1/en active Active
- 2013-12-20 JP JP2015549830A patent/JP6306607B2/ja active Active
- 2013-12-20 US US14/137,479 patent/US9169248B2/en active Active
- 2013-12-20 ES ES13866291.1T patent/ES2648994T3/es active Active
- 2013-12-20 PT PT138662911T patent/PT2935227T/pt unknown
- 2013-12-20 CA CA2894715A patent/CA2894715C/en active Active
- 2013-12-20 DK DK13866291.1T patent/DK2935227T3/en active
- 2013-12-20 AU AU2013364038A patent/AU2013364038B2/en active Active
- 2013-12-20 MX MX2015007853A patent/MX2015007853A/es active IP Right Grant
- 2013-12-20 CN CN201380067710.XA patent/CN104918921B/zh active Active
- 2013-12-20 WO PCT/US2013/077257 patent/WO2014100735A2/en not_active Ceased
-
2015
- 2015-10-08 US US14/878,784 patent/US9750722B2/en active Active
-
2017
- 2017-07-25 US US15/659,488 patent/US10342781B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016507504A5 (enExample) | ||
| JP2016501246A5 (enExample) | ||
| JP2012502111A5 (enExample) | ||
| JP2015509535A5 (enExample) | ||
| JP2014503001A5 (enExample) | ||
| JP2016514159A5 (enExample) | ||
| JP2011528658A5 (enExample) | ||
| RU2015127027A (ru) | Диазольные лактамы | |
| JP2015518821A5 (enExample) | ||
| JP2012092103A5 (enExample) | ||
| JP2014503525A5 (enExample) | ||
| JP2016529315A5 (enExample) | ||
| RU2014136394A (ru) | Морфолиноалкилфумаратные соединения, фармацевтические композиции и способы применения | |
| JP2016503793A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| JP2012500805A5 (enExample) | ||
| JP2011527667A5 (enExample) | ||
| JP2016518317A5 (enExample) | ||
| JP2015501799A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2017511321A5 (enExample) | ||
| JP2015520770A5 (enExample) | ||
| JP2018500287A5 (enExample) | ||
| JP2016539985A5 (enExample) | ||
| JP2014505032A5 (enExample) |